MAPT and hippocampal atrophy: In WRAP, in determining abnormal Aβ PET, plasma p-tau217 outperformed hippocampal atrophy (AUC, 0.52; 95% CI, 0.44-0.60; P < .001), tau PET (AUC, 0.72; 95% CI, 0.64-0.80; P < .001), and CSF p-tau181 (AUC, 0.75; 95% CI, 0.66-0.84; P < .001) but did not differ significantly from CSF Aβ42/40 or CSF p-tau181/Aβ42 (eFigure 5A in Supplement 1).